Cepheid and the Foundation for Innovative New Diagnostics (FIND) have launched a new portable molecular diagnostics system for patients with suspected tuberculosis (TB), HIV and Ebola.
The system was launched at the ongoing American Association of Clinical Chemistry (AACC) meeting in Atlanta, Georgia, US.
Claimed to be the world’s most portable molecular diagnostics system, GeneXpert Omni will run the same high-quality PCR-based cartridge tests as Cepheid’s family of GeneXpert systems.
The battery operated, wireless and web-enabled system is expected to enable true point-of-care testing for life-threatening conditions, including TB, drug-resistant TB, HIV and Ebola, to be conducted on demand at the patient’s location.
Cepheid CEO John Bishop said: "For too long, access to best-in-class molecular diagnostics has been limited by the complexity of the tests and the systems that run them.
"With the GeneXpert Omni, global accessibility to molecular diagnostics is possible for the first time.
"The system’s unprecedented portability means that it can literally go anywhere, and deliver critical diagnostic test results to support disease determination, treatment and improved patient outcomes."
World Health Organisation (WHO) Global TB programme director Dr Mario Raviglione said: "This new point-of-care diagnostic platform has the potential to transform our capacity to detect the world’s missing three million TB cases."
GeneXpert Omni is expected to be available for customers outside the US in the first half of 2016.
The available test menu is expected to comprise Xpert MTB Ultra, Xpert HIV-1 Qualitative, Xpert HIV-1 Viral Load, Xpert HCV Viral Load and Xpert Ebola.
Working in collaboration with not-for-profit organisations, Cepheid is expanding access to quality molecular diagnostics with Xpert MTB/RIF, a test that was backed by WHO in December 2010.
Image: GeneXpert Omni will provide life-saving diagnosis for patients suspected of having TB, HIV and Ebola. Photo: courtesy of Cepheid.